Keywords: Sanofi-Aventis, AEterna Zentaris, Cetrole4lix, Prostatic hyperplasia, Cancer, Termination of licensing deal

Sanofi-Aventis pulls out of deal with AEterna Zentaris on Cetrorelix in benign prostatic hyperplasia

Article | 21 December 2009

Print This

French drug major Sanofi-Aventis has pulled out of its deal with Canada’s AEterna Zentaris for the development, commercialization and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in